clinical trial · NCT07025239
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer
Qilu Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 430
Metastatic Colorectal CancerQL1706BevacizumabOxaliplatinCapecitabinePlacebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of QL1706 Injection in combination with bevacizumab and XELOX compared with placebo in combination with bevacizumab and XELOX for first-line treatment in patients with unresectable mCRC.
started
Jul 1, 2025
primary completion
Jul 1, 2028
completion
Jul 1, 2029
last updated
Jun 17, 2025
official title
A Randomized, Double-blind, Multicenter Phase 3 Study of QL1706 Injection in Combination With Bevacizumab and XELOX Versus Placebo in Combination With Bevacizumab and XELOX as First-line Therapy for the Treatment of Patients With Unresectable Metastatic Colorectal Cancer (mCRC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol